Review article · 2026 · Open access
Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Journal of Personalized Medicine, 16(2), 113 · Published 13 February 2026 · DOI 10.3390/jpm16020113
In brief
“Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis” is a 2026 review article by Diomidis C. Ioannidis and 3 co-authors, published in Journal of Personalized Medicine. OpenAlex counts 1 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Personalized Medicine.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.86
- References
- 53
- Authors
- 4
Abstract
Background/Objectives: Janus Kinase inhibitors (JAKi) are an effective treatment option for rheumatoid arthritis (RA); however, emerging concerns regarding cardiovascular and thromboembolic risk have prompted further investigation. We conducted a systematic review and meta-analysis to compare the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in patients receiving JAKi versus other disease-modifying anti-rheumatic drugs (DMARDs). Methods: Following PRISMA 2020 guidelines and a preregistered protocol, we systematically searched PubMed, Embase, and the Cochrane Library. Observational studies and randomized controlled trials (RCTs) reporting MACE or VTE among adults with RA treated with JAKi or comparator DMARDs were included. Hazard ratios (HRs) from observational studies and odds ratios (ORs) from RCTs were pooled using fixed- or random-effects models depending on heterogeneity. A sensitivity analysis was conducted for participants aged ≥ 65 years. Results: Twenty-five observational studies and eight RCTs were included. Across observational studies, the pooled HRs for MACE showed no significant difference between JAKi and other DMARDs, HR = 0.98, 95% CI = 0.85–1.13. This finding remained consistent in individuals aged ≥ 65 years. No increase in MACE risk was observed across RCTs, OR = 1.27, 95% CI = 0.89–1.81. In contrast, JAKi use was associated with a significantly higher risk of VTE in the observational studies (HR = 1.32, 95% CI = 1.08–1.61) but not in the RCTs (OR = 1.69, 95% CI = 0.94–3.02). Conclusions: JAKi use does not appear to increase the risk of MACE compared to DMARDs, including in older adults, but may be associated with a higher risk of VTE. These findings highlight the importance of a personalized approach when considering JAKi therapy, incorporating structured cardiovascular and thrombotic risk assessment, patient preferences, and mitigation of modifiable risk factors.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Ioannidis, D. C., Kapasouri, E. M., Vassiliou, V. S., & Ntatsaki, E. (2026). Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 16(2), 113. https://doi.org/10.3390/jpm16020113
MLA 9
Ioannidis, Diomidis C., et al. “Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Journal of Personalized Medicine, vol. 16, no. 2, 2026, p. 113. https://doi.org/10.3390/jpm16020113.
Chicago
Ioannidis, Diomidis C., Efthymia Maria Kapasouri, Vassilios S. Vassiliou, and Eleana Ntatsaki. 2026. “Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Journal of Personalized Medicine 16 (2): 113. https://doi.org/10.3390/jpm16020113.
Harvard
Ioannidis, D. C. et al. (2026) ‘Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis’, Journal of Personalized Medicine, 16(2), p. 113. doi:10.3390/jpm16020113.
IEEE
D. C. Ioannidis, E. M. Kapasouri, V. S. Vassiliou, and E. Ntatsaki, “Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis,” Journal of Personalized Medicine, vol. 16, no. 2, p. 113, 2026, doi: 10.3390/jpm16020113.
BibTeX
@article{ioannidis2026cardiovascular,
title = {{Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis}},
author = {Ioannidis, Diomidis C. and Kapasouri, Efthymia Maria and Vassiliou, Vassilios S. and Ntatsaki, Eleana},
journal = {Journal of Personalized Medicine},
year = {2026},
volume = {16},
number = {2},
pages = {113},
doi = {10.3390/jpm16020113},
url = {https://doi.org/10.3390/jpm16020113}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- JAK inhibitors
- rheumatoid arthritis
- major adverse cardiovascular events
- venous thromboembolism
- disease-modifying antirheumatic drugs
- cardiovascular risk
- thromboembolic risk
- older adults
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Ioannidis, D. C., Kapasouri, E. M., Vassiliou, V. S., & Ntatsaki, E. (2026). Cardiovascular and Thromboembolic Risk of Janus Kinase Inhibitors Compared to Other Disease-Modifying Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 16(2), 113. https://doi.org/10.3390/jpm16020113
How many times has this paper been cited?
1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Personalized Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Diomidis C. Ioannidis, Efthymia Maria Kapasouri, Vassilios S. Vassiliou, Eleana Ntatsaki.
What is the DOI of this paper?
10.3390/jpm16020113, permanently at https://doi.org/10.3390/jpm16020113. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.